Key result
Real-world TARGET-NASH cohort characterizes statin use patterns and clinical predictors in NAFLD.
Cohort
Answers are grounded in this paper and cite their sources.
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events.1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis,2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma.3,4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity.5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.
No takes yet. Share an insight, caveat, or question.
Thomson et al. (2021) conducted a cohort in Nonalcoholic fatty liver disease (NAFLD). Statin use was evaluated on Prevalence and patient factors associated with indicated statin use. Statin use prevalence and associated patient factors were evaluated among patients with NAFLD in the real-world TARGET-NASH cohort (no quantitative results reported in abstract).
Synapse has enriched 10 related papers. Consider them for comparative context: